British pharmaceutical giant GlaxoSmithKline (GSK.L) announced on Wednesday that extended data analysis confirms the continued robust efficacy of its widely-used shingles vaccine, Shingrix, even years after initial administration.
According to GSK’s statement, long-term observations revealed that Shingrix maintained a 79.7% efficacy rate among individuals aged 50 years and older, spanning from six to 11 years post-vaccination. Notably, the vaccine’s effectiveness remained notably high at 82% even after 11 years following the initial dose.
This data stems from a comprehensive long-term follow-up study, conducted at the late-stage, which meticulously monitored participants for approximately 11 years subsequent to their initial Shingrix inoculation.
The findings underscore the enduring efficacy of Shingrix in protecting against shingles, a viral infection characterized by a painful rash, particularly in older adults. GSK’s reaffirmation of Shingrix’s effectiveness over an extended duration reaffirms the vaccine’s crucial role in mitigating the risks associated with shingles among the aging population.
